Evidence map›Paper›PMID 33752274›Full record

ArticleDiabetes & metabolism journal2021

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.

Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & metabolism journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 10 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 10 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Review
  12. Review
  13. Article
  14. Review
  15. ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sang Youl RheeDepartment of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
Jeongwoo LeeData Science Team, Hanmi Pharm. Co. Ltd., Seoul, Korea.
Hyewon NamData Science Team, Hanmi Pharm. Co. Ltd., Seoul, Korea.
Dae-Sung KyoungData Science Team, Hanmi Pharm. Co. Ltd., Seoul, Korea.
Dong Wook ShinDepartment of Family Medicine, Supportive Care Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Dae Jung KimDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
Hanmi Pharmaceutical (South Korea) · KRAjou University · KRKyung Hee University · KRSamsung Medical Center · KR

Funding

Korean Endocrine Society of EnM
6 · The paper itself

Abstract

backgroundDipeptidyl peptidase-4 inhibitor (DPP-4i) and renin-angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM).

methodsAs of May 2020, analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Insurance Review and Assessment Service (HIRA) database in Korea. Using this dataset, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade. Additionally, we validated the results using the National Health Insurance Service (NHIS) of Korea dataset.

resultsTotally, data of 67,850 subjects were accessible in the HIRA dataset. Of these, 5,080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 (95% confidence interval [CI], 0.135 to 0.971), and that for RAS blockade users was 0.599 (95% CI, 0.251 to 1.431). These findings were consistent with the analysis based on the NHIS data using 704 final subjects. The adjusted odds ratio for severe treatment among DPP-4i users was 0.303 (95% CI, 0.135 to 0.682), and that for RAS blockade users was 0.811 (95% CI, 0.391 to 1.682).

conclusionThis study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19.

Indexed as

COVID-19 Drug TreatmentAdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCOVID-19Databases, FactualDiabetes MellitusDipeptidyl-Peptidase IV InhibitorsFemaleHumansMaleMiddle AgedNational Health ProgramsRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDipeptidyl-Peptidase IV InhibitorsAngiotensin-converting enzyme 2COVID-19COVID-19 drug treatmentDiabetes mellitusDipeptidyl peptidase 4

Identifiers

PMID33752274
PMCPMC8024148
OpenAlexW3134804907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.